|
Daily Medical Update
Glomerular hematuria
Monday, August 17, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Kidney international (2025) - Practice Guideline
Key Findings
- The updated guideline recommends a more liberal kidney-biopsy policy, increasing diagnostic access for suspected glomerular disease.
- It recommends reducing proteinuria below 0.5 g/day, ideally below 0.3 g/day, while maintaining stable eGFR.
- It recommends combining therapies that reduce pathogenic IgA or immune-complex formation with measures that address existing nephron loss, including renin–angiotensin system blockade and SGLT2 inhibition.
📋 Practice Implication: Use the updated framework to lower the threshold for diagnostic biopsy and to manage IgAN with explicit proteinuria targets plus complementary disease-modifying and supportive therapy.
|
Clinical journal of the American Society of Nephrology : CJASN (2025) - Meta-Analysis
Key Findings
- Baseline proteinuria of 0.5–1.0 g/day was associated with higher risk of adverse kidney outcomes than proteinuria below 0.5 g/day (pooled HR 1.73, 95% CI 1.36–2.20).
- Time-averaged low-grade proteinuria was associated with an even higher kidney-outcome risk (pooled HR 2.87, 95% CI 1.48–5.56).
- Time-averaged low-grade proteinuria corresponded to a steeper annual eGFR decline of 1.02 mL/min/1.73 m² (95% CI 0.45–1.60) in the unfavorable direction.
📋 Practice Implication: Treat persistent proteinuria in the 0.5–1.0 g/day range as clinically meaningful residual risk, rather than as a reassuring level that warrants observation alone.
|
BMC nephrology (2026) - Network Meta-Analysis
Key Findings
- Azathioprine plus cyclophosphamide ranked highest for 24-hour proteinuria reduction, but it also had poor renal-failure and safety rankings.
- BAFF/APRIL inhibitors and endothelin-receptor antagonists ranked above systemic corticosteroids for UPCR reduction.
- SGLT2 inhibitors ranked second for ESRD risk reduction and maintained a favorable safety profile, while systemic corticosteroids and targeted-release budesonide balanced proteinuria reduction with slower renal failure progression.
📋 Practice Implication: Choose therapy by the treatment endpoint: avoid interpreting maximal antiproteinuric ranking as overall superiority, and weigh renal protection and toxicity when considering cytotoxic or steroid-based regimens.
|
BMC nephrology (2026) - Systematic Review
Key Findings
- Sibeprenlimab reduced UPCR more than control by 48.35 percentage points (95% CI 34.69–62.00).
- Fewer patients experienced hematuria with sibeprenlimab than with control (OR 0.11, 95% CI 0.06–0.20).
- Sibeprenlimab improved the least-squares mean eGFR change by 6.11 mL/min/1.73 m² and reduced circulating Gd-IgA1 and serum APRIL levels.
- Overall adverse-event incidence was comparable with control, while serum IgG, IgA, and IgM were reduced more with sibeprenlimab.
📋 Practice Implication: Sibeprenlimab is a promising targeted option when proteinuria and hematuria remain active, but immunoglobulin levels should be monitored because biomarker improvement may accompany reduced humoral immunity.
|
Journal of nephrology (2026) - Systematic Review
Key Findings
- BAFF- or APRIL-targeted drugs reduced 24-hour UPCR versus placebo by 38.94% (95% CI 18.90–58.98).
- The therapies improved eGFR versus placebo by 7.05 mL/min/1.73 m² (95% CI 3.83–10.27).
- Adverse-event rates did not significantly differ from placebo, while serum Gd-IgA1, IgG, IgA, and IgM were all reduced.
📋 Practice Implication: The class-level signal supports BAFF/APRIL pathway inhibition as a biologically coherent approach, while the immunoglobulin reductions argue for infection-risk surveillance and longer-term safety follow-up.
|
|
💡
Summary
The selected evidence is concentrated in IgA nephropathy and supports tighter proteinuria control, updated biopsy practice, and a dual strategy addressing pathogenic IgA production plus nephron-loss consequences. Targeted BAFF/APRIL therapies consistently reduced proteinuria, with sibeprenlimab also reducing hematuria and circulating disease biomarkers, while comparative evidence highlights efficacy–toxicity trade-offs among immunosuppressive regimens.
|
|